Androgel Is FTC's Best Shot At High Court Pay-For-Delay Case

Law360, New York (July 19, 2012, 9:44 PM EDT) -- The Eleventh Circuit's refusal Wednesday to rehear the Federal Trade Commission's case against settlements Solvay Pharmaceutical Inc. made with generic Androgel makers — just two days after the Third Circuit created a clear appellate split on the issue — has given the agency its best shot at having the U.S. Supreme Court take up its decadelong campaign against pay-for-delay deals.

Though the justices repeatedly have refused to hear litigation challenging the settlements between brand- and generic-drug makers in the past, the textbook split between the Eleventh...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.